|
|
||||||||
-cell function in subjects with normal or impaired glucose tolerance
1Department of Internal Medicine and Consiglio Nazionale delle Ricerche (CNR) Institute of Clinical Physiology, University of Pisa; 2CNR Institute of Biochemical Engineering, Padua, Italy; and 3Department of Medical Physiology, Panum Institute, Copenhagen, Denmark
Submitted 21 November 2005 ; accepted in final form 9 February 2006
The mechanisms by which the enteroinsular axis influences
-cell function have not been investigated in detail. We performed oral and isoglycemic intravenous (IV) glucose administration in subjects with normal (NGT; n = 11) or impaired glucose tolerance (IGT; n = 10), using C-peptide deconvolution to calculate insulin secretion rates and mathematical modeling to quantitate
-cell function. The incretin effect was taken to be the ratio of oral to IV responses. In NGT, incretin-mediated insulin release [oral glucose tolerance test (OGTT)/IV ratio = 1.59 ± 0.18, P = 0.004] amounted to 18 ± 2 nmol/m2 (32 ± 4% of oral response), and its time course matched that of total insulin secretion. The
-cell glucose sensitivity (OGTT/IV ratio = 1.52 ± 0.26, P = 0.02), rate sensitivity (response to glucose rate of change, OGTT/IV ratio = 2.22 ± 0.37, P = 0.06), and glucose-independent potentiation were markedly higher with oral than IV glucose. In IGT,
-cell glucose sensitivity (75 ± 14 vs. 156 ± 28 pmol·min1·m2·mM1 of NGT, P = 0.01) and potentiation were impaired on the OGTT. The incretin effect was not significantly different from NGT in terms of plasma glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide responses, total insulin secretion, and enhancement of
-cell glucose sensitivity (OGTT/IV ratio = 1.73 ± 0.24, P = NS vs. NGT). However, the time courses of incretin-mediated insulin secretion and potentiation were altered, with a predominance of glucose-induced vs. incretin-mediated stimulation. We conclude that, under physiological circumstances, incretin-mediated stimulation of insulin secretion results from an enhancement of all dynamic aspects of
-cell function, particularly
-cell glucose sensitivity. In IGT,
-cell function is inherently impaired, whereas the incretin effect is only partially affected.
glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; insulin secretion
This article has been cited by other articles:
![]() |
E. Muscelli, A. Mari, A. Casolaro, S. Camastra, G. Seghieri, A. Gastaldelli, J. J. Holst, and E. Ferrannini Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients Diabetes, May 1, 2008; 57(5): 1340 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. K. Knop, T. Vilsboll, P. V. Hojberg, S. Larsen, S. Madsbad, A. Volund, J. J. Holst, and T. Krarup Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State? Diabetes, August 1, 2007; 56(8): 1951 - 1959. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Salinari, A. Bertuzzi, M. Manco, and G. Mingrone NEFA-glucose comodulation model of beta-cell insulin secretion in 24-h multiple-meal test Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1890 - E1898. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |